Abaloparatide prevents immobilization-induced cortical but not trabecular bone loss after spinal cord injury.

Sahbani K, Pan J, Zaidi M, Cardozo CP, Bauman WA, Tawfeek HA

FASEB journal : official publication of the Federation of American Societies for Experimental Biology1 Jun 2023Cited by 4 (Europe PMC)

PMID37219516DOI10.1096/fj.202300109rrPepBankPUB-37219516

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In spinal cord-injured mice, abaloparatide did not prevent trabecular bone changes compared with SCI vehicle.
In plain wordsIn mice with spinal cord injury, abaloparatide did not prevent trabecular bone changes compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeTrabecular bone loss at lower dose
Study
mousen: not reported in source
Female mice with contusion thoracic spinal cord injury
Comparator
SCI-vehicle mice
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/kg/day · subcutaneous injection · 35 daysAs given in this study (mouse).
Source sentences
Summary
Treatment with abaloparatide did not prevent SCI-induced changes in trabecular or cortical bone.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, female mice underwent sham or severe contusion thoracic SCI causing hindlimb paralysis.
Summary · context
Mice then received subcutaneous injection of vehicle or 20 μg/kg/day abaloparatide for 35 days.
Report a problemFND-3721951601
02AnimalAnimal study (in vivo)Efficacy outcome
In spinal cord-injured mice, abaloparatide did not prevent cortical bone changes compared with SCI vehicle.
In plain wordsIn mice with spinal cord injury, abaloparatide did not prevent cortical bone changes compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeCortical bone loss at lower dose
Study
mousen: not reported in source
Female mice with contusion thoracic spinal cord injury
Comparator
SCI-vehicle mice
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/kg/day · subcutaneous injection · 35 daysAs given in this study (mouse).
Source sentences
Summary
Treatment with abaloparatide did not prevent SCI-induced changes in trabecular or cortical bone.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, female mice underwent sham or severe contusion thoracic SCI causing hindlimb paralysis.
Summary · context
Mice then received subcutaneous injection of vehicle or 20 μg/kg/day abaloparatide for 35 days.
Report a problemFND-3721951602
03AnimalAnimal study (in vivo)Efficacy outcome
In spinal cord-injured mice, abaloparatide increased osteoblast numbers compared with SCI vehicle.
In plain wordsIn mice with spinal cord injury, abaloparatide increased bone-forming cell numbers compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseOsteoblast numbers
Study
mousen: not reported in source
Female mice with contusion thoracic spinal cord injury
Comparator
SCI-vehicle mice
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/kg/day · subcutaneous injection · 35 daysAs given in this study (mouse).
Measurements
Osteoblast numbers
241%
versus SCI vehicle
Source sentences
Summary
However, histomorphometry evaluation of the SCI-abaloparatide mice demonstrated that abaloparatide treatment increased osteoblast (241%) and osteoclast (247%) numbers and the mineral apposition rate (131%) compared to SCI-vehicle animals.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, female mice underwent sham or severe contusion thoracic SCI causing hindlimb paralysis.
Summary · context
Mice then received subcutaneous injection of vehicle or 20 μg/kg/day abaloparatide for 35 days.
Report a problemFND-3721951603
04AnimalAnimal study (in vivo)Efficacy outcome
In spinal cord-injured mice, abaloparatide increased osteoclast numbers compared with SCI vehicle.
In plain wordsIn mice with spinal cord injury, abaloparatide increased bone-resorbing cell numbers compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseOsteoclast numbers
Study
mousen: not reported in source
Female mice with contusion thoracic spinal cord injury
Comparator
SCI-vehicle mice
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/kg/day · subcutaneous injection · 35 daysAs given in this study (mouse).
Measurements
Osteoclast numbers
247%
versus SCI vehicle
Source sentences
Summary
However, histomorphometry evaluation of the SCI-abaloparatide mice demonstrated that abaloparatide treatment increased osteoblast (241%) and osteoclast (247%) numbers and the mineral apposition rate (131%) compared to SCI-vehicle animals.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, female mice underwent sham or severe contusion thoracic SCI causing hindlimb paralysis.
Summary · context
Mice then received subcutaneous injection of vehicle or 20 μg/kg/day abaloparatide for 35 days.
Report a problemFND-3721951604
05AnimalAnimal study (in vivo)Efficacy outcome
In spinal cord-injured mice, abaloparatide increased mineral apposition rate compared with SCI vehicle.
In plain wordsIn mice with spinal cord injury, abaloparatide increased the rate of bone mineral deposition compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseMineral apposition rate
Study
mousen: not reported in source
Female mice with contusion thoracic spinal cord injury
Comparator
SCI-vehicle mice
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/kg/day · subcutaneous injection · 35 daysAs given in this study (mouse).
Measurements
Mineral apposition rate
131%
versus SCI vehicle
Source sentences
Summary
However, histomorphometry evaluation of the SCI-abaloparatide mice demonstrated that abaloparatide treatment increased osteoblast (241%) and osteoclast (247%) numbers and the mineral apposition rate (131%) compared to SCI-vehicle animals.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, female mice underwent sham or severe contusion thoracic SCI causing hindlimb paralysis.
Summary · context
Mice then received subcutaneous injection of vehicle or 20 μg/kg/day abaloparatide for 35 days.
Report a problemFND-3721951605
06AnimalAnimal study (in vivo)Efficacy outcome
In spinal cord-injured mice, higher-dose abaloparatide significantly attenuated cortical thinning compared with SCI vehicle.
In plain wordsIn mice with spinal cord injury, higher-dose abaloparatide reduced cortical thinning compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCortical thickness at higher dose
Study
mousen: not reported in source
Female mice with contusion thoracic spinal cord injury
Comparator
SCI-vehicle mice
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 μg/kg/dayAs given in this study (mouse).
Measurements
Cortical thickness
93%
SCI abaloparatide
Cortical thickness
79%
SCI vehicle
Source sentences
Summary
In another independent experiment, treatment with 80 μg/kg/day abaloparatide significantly attenuated SCI-induced loss in cortical bone thickness (93%) when compared to SCI-vehicle mice (79%) but did not prevent SCI-induced trabecular bone loss or elevation in cortical porosity.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, female mice underwent sham or severe contusion thoracic SCI causing hindlimb paralysis.
Summary · context
Mice then received subcutaneous injection of vehicle or 20 μg/kg/day abaloparatide for 35 days.
Report a problemFND-3721951606
07AnimalAnimal study (in vivo)Efficacy outcome
In spinal cord-injured mice, higher-dose abaloparatide did not prevent trabecular bone loss compared with SCI vehicle.
In plain wordsIn mice with spinal cord injury, higher-dose abaloparatide did not prevent trabecular bone loss compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeTrabecular bone loss at higher dose
Study
mousen: not reported in source
Female mice with contusion thoracic spinal cord injury
Comparator
SCI-vehicle mice
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 μg/kg/dayAs given in this study (mouse).
Source sentences
Summary
In another independent experiment, treatment with 80 μg/kg/day abaloparatide significantly attenuated SCI-induced loss in cortical bone thickness (93%) when compared to SCI-vehicle mice (79%) but did not prevent SCI-induced trabecular bone loss or elevation in cortical porosity.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, female mice underwent sham or severe contusion thoracic SCI causing hindlimb paralysis.
Summary · context
Mice then received subcutaneous injection of vehicle or 20 μg/kg/day abaloparatide for 35 days.
Report a problemFND-3721951607
08AnimalAnimal study (in vivo)Efficacy outcome
In spinal cord-injured mice, higher-dose abaloparatide did not prevent increased cortical porosity compared with SCI vehicle.
In plain wordsIn mice with spinal cord injury, higher-dose abaloparatide did not prevent increased cortical porosity compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeCortical porosity at higher dose
Study
mousen: not reported in source
Female mice with contusion thoracic spinal cord injury
Comparator
SCI-vehicle mice
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 μg/kg/dayAs given in this study (mouse).
Source sentences
Summary
In another independent experiment, treatment with 80 μg/kg/day abaloparatide significantly attenuated SCI-induced loss in cortical bone thickness (93%) when compared to SCI-vehicle mice (79%) but did not prevent SCI-induced trabecular bone loss or elevation in cortical porosity.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, female mice underwent sham or severe contusion thoracic SCI causing hindlimb paralysis.
Summary · context
Mice then received subcutaneous injection of vehicle or 20 μg/kg/day abaloparatide for 35 days.
Report a problemFND-3721951608
09AnimalAnimal study (in vivo)Efficacy outcome
In spinal cord-injured mice, abaloparatide increased bone marrow procollagen type I N-terminal propeptide compared with SCI vehicle.
In plain wordsIn mice with spinal cord injury, abaloparatide increased a bone formation marker in bone marrow compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseBone marrow procollagen type I N-terminal propeptide
Study
mousen: not reported in source
Female mice with contusion thoracic spinal cord injury
Comparator
SCI-vehicle mice
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Procollagen type I N-terminal propeptide
2.3 fold
versus SCI vehicle
Source sentences
Summary
Biochemical analysis of the bone marrow supernatants of the femurs showed that SCI-abaloparatide animals had 2.3-fold increase in procollagen type I N-terminal propeptide, a bone formation marker than SCI-vehicle animals.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, female mice underwent sham or severe contusion thoracic SCI causing hindlimb paralysis.
Summary · context
Mice then received subcutaneous injection of vehicle or 20 μg/kg/day abaloparatide for 35 days.
Report a problemFND-3721951609

Studies that did not test the peptide alone1

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

10AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome
In mice, spinal cord injury groups, including abaloparatide-treated animals, had higher cross-linked C-telopeptide levels than sham vehicle controls.
In plain wordsIn mice, injured groups including abaloparatide-treated animals had higher bone resorption marker levels than sham controls.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCross-linked C-telopeptide after injury
Study
mousen: not reported in source
Female mice with contusion thoracic spinal cord injury
Comparator
Sham-vehicle mice
Outcome group
Bone and joint · Musculoskeletal
Measurements
Cross-linked C-telopeptide increase
70%
SCI groups versus sham vehicle
Source sentences
Summary
SCI groups had 70% higher levels of cross-linked C-telopeptide of type I collagen, a bone resorption marker, than sham-vehicle mice.
2 context sentences(design, population, supporting numbers)
Summary · context
Thus, female mice underwent sham or severe contusion thoracic SCI causing hindlimb paralysis.
Summary · context
Mice then received subcutaneous injection of vehicle or 20 μg/kg/day abaloparatide for 35 days.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3721951610

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.